⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050020 | 0.95 | — | — | |
| SCHEMBL7269245 | 0.95 | — | — | |
| SCHEMBL14048657 | 0.95 | — | — | |
| SCHEMBL214730 | 0.95 | — | — | |
| SCHEMBL6050015 | 0.90 | — | — | |
| SCHEMBL6811891 | 0.82 | — | — | |
| SCHEMBL327803 | 0.82 | — | — | |
| SCHEMBL13729125 | 0.82 | — | — | |
| SCHEMBL14389042 | 0.82 | — | — | |
| SCHEMBL5751382 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230034585-A1 | EXTRACELLULAR MATRIX SYSTEMS, DEVICES, AND METHODS OF DEPLOYMENT | RENERVA, LLC | 2023-02-02 | — | — | US | disclosed |
| CN-115066291-A | Aqueous capsule suspension concentrates based on polyurea shell materials containing polyfunctional aminocarboxylate esters | 拜耳公司 | 2022-09-16 | — | — | CN | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3939964-A1 | COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3204040-B1 | TREATMENT OF CANCER USING TLR9 AGONISTS AND CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3351248-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20200268741-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| CN-106061250-B | Water dispersible granular composition | 迪帕克·沙阿 | 2020-03-27 | — | — | CN | disclosed |
| US-10543207-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20120142907-A1 | MODIFIED MACROMOLECULES AND ASSOCIATED METHODS OF SYNTHESIS AND USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2012-06-07 | — | — | US | disclosed |
| US-20120063991-A1 | METHOD OF TREATING AN ACID GAS STREAM AND AN APPARATUS THEREFOR | SHELL OIL COMPANY | 2012-03-15 | — | — | US | disclosed |
| WO-2010078449-A2 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |